Journal article

Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study

Abstract:: Antecedentes: la depresión, es un trastorno que afecta a un 8-12% de la población general. A pesar de los avances en el desarrollo de los fármacos antidepresivos, gran número de la población sigue teniendo multitud de respuestas adversas a éstos, siendo motivo, en muchas ocasiones, de rechazo al tratamiento y hospitalización. Buena parte de estos problemas podrían resolverse con la práctica de la farmacogenética, es decir, ofreciendo un tratamiento personalizado, considerando que cada individ...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Campos, A. I., Byrne, E. M., Mitchell, B. L., Wray, N. R., Lind, P. A., Licinio, J., Medland, S. E., Martin, N. G., Hickie, I. B., & Rentería, M. E. (2022). Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study. Pharmacogenomics Journal, 22(2), 130–135.

MLA Style

Campos, AI, et al. “Impact of CYP2C19 Metaboliser Status on SSRI Response: a Retrospective Study of 9500 Participants of the Australian Genetics of Depression Study.” Pharmacogenomics Journal, vol. 22, no. 2, 2022, pp. 130–35.

Chicago Style

Campos, AI, EM Byrne, BL Mitchell, et al. 2022. “Impact of CYP2C19 Metaboliser Status on SSRI Response: a Retrospective Study of 9500 Participants of the Australian Genetics of Depression Study.” Pharmacogenomics Journal 22 (2): 130–35.
Print

Access Document

Files:: Campos_et_al_2022_Impact_of_CYP2C19.pdf

(Preview, Version of record, pdf, 618.7KB, Terms of use)

Publisher copy:: 10.1038/s41397-022-00267-7

Publication website:: https://academica-e.unavarra.es/xmlui/bitstream/2454/45620/1/TFG.%20Iranzu%20Alzueta%20Ayerra.pdf

Authors

+ Campos, AI More by this author

Role:: Author
ORCID:: 0000-0003-3468-8619

+ Byrne, EM More by this author

Role:: Author
ORCID:: 0000-0002-9491-7797

+ Mitchell, BL More by this author

Role:: Author
ORCID:: 0000-0002-9050-1516

+ Wray, NR More by this author

Institution:: University of Oxford
Role:: Author
ORCID:: 0000-0001-7421-3357

+ Lind, PA More by this author

Role:: Author
ORCID:: 0000-0002-3887-2598

More authors...

+ Department of Health | National Health and Medical Research Council More from this funder

Funder identifier:: 10.13039/501100000925
Grant:: GNT1086683

Publisher:: Springer Nature [academic journals on nature.com]
Journal:: Pharmacogenomics Journal More from this journal
Volume:: 22
Issue:: 2
Pages:: 130-135
Publication date:: 2022-01-29
DOI:: 10.1038/s41397-022-00267-7
EISSN:: 1473-1150
ISSN:: 1470-269X

Language:: Spanish
Keywords:: Tolerability

Medicine

Genotype

Odds ratio

Pharmacology

Genetics

Biology

Internal medicine

Pharmacogenetics

CYP2C19

Antidepressant

Adverse effect

Sertraline

Serotonin reuptake inhibitor
Pubs id:: 1375982
Local pid:: pubs:1375982
Source identifiers:: W4210495840
Deposit date:: 2026-05-08
ARK identifier:: ark:/29072/ora_68779b2153504679ae699f072e416c20

Terms of use

Copyright date:: 2022

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP